Fertility and sterility · 2011
The utility and cost of Chlamydia trachomatis and Neisseria gonorrhoeae screening of a male infertility population.
Оценочное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Domes Trustin, Lo Kirk C, Grober Ethan D, Mullen J Brendan, Mazzulli Tony, Jarvi Keith
Аннотация
OBJECTIVE: To determine the utility and cost of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) screening in infertile males.
DESIGN: Cohort study.
SETTING: Canadian tertiary-level male infertility clinic and university-affiliated laboratories.
PATIENT(S): 5,588 male infertility patients.
INTERVENTION(S): CT and NG testing on 8,972 urine and semen samples.
MAIN OUTCOME MEASURE(S): Prevalence of CT and NG infection in infertile males versus general male population in Canada over 8 years (2003-2010) and the reagent cost to detect one case of CT or NG.
RESULT(S): In infertile males, the prevalence rate for CT and NG was 0.304% and 0.0537%, which was statistically significantly lower (3.4- and 8.1-fold lower, respectively) than the age-adjusted general population prevalence. With the reagents costing $86.20 per patient tested, the reagent cost alone to diagnose one case of CT or NG was $38,669.
CONCLUSION(S): The prevalence of CT and NG in this study are among the lowest reported in the male infertility literature. These findings question the utility of CT/NG screening in this low-risk population and emphasize that decisions about the utility of screening must be based on the prevalence rates of the disease in the studied population.
DESIGN: Cohort study.
SETTING: Canadian tertiary-level male infertility clinic and university-affiliated laboratories.
PATIENT(S): 5,588 male infertility patients.
INTERVENTION(S): CT and NG testing on 8,972 urine and semen samples.
MAIN OUTCOME MEASURE(S): Prevalence of CT and NG infection in infertile males versus general male population in Canada over 8 years (2003-2010) and the reagent cost to detect one case of CT or NG.
RESULT(S): In infertile males, the prevalence rate for CT and NG was 0.304% and 0.0537%, which was statistically significantly lower (3.4- and 8.1-fold lower, respectively) than the age-adjusted general population prevalence. With the reagents costing $86.20 per patient tested, the reagent cost alone to diagnose one case of CT or NG was $38,669.
CONCLUSION(S): The prevalence of CT and NG in this study are among the lowest reported in the male infertility literature. These findings question the utility of CT/NG screening in this low-risk population and emphasize that decisions about the utility of screening must be based on the prevalence rates of the disease in the studied population.
Предметные рубрики MeSH
AdolescentAdultChi-Square DistributionChlamydia InfectionsChlamydia trachomatisCost-Benefit AnalysisGonorrheaHealth Care CostsHumansInfertility, MaleMaleMass ScreeningMiddle AgedModels, EconomicNeisseria gonorrhoeaeOntarioPredictive Value of TestsPrevalenceProgram EvaluationRetrospective StudiesYoung Adult